Evidence map›Paper›PMID 33129896›Full record

ArticleKidney international2021

Complement activity is regulated in C3 glomerulopathy by IgG-factor H fusion proteins with and without properdin targeting domains.

Alyssa C Gilmore, Yuchun Zhang, H Terence Cook, Deborah P Lavin, Suresh Katti, Yi Wang, Krista K Johnson, SungKwon Kim, Matthew C Pickering

Open access · hybridAbstract read
In one paragraph

Article in Kidney international, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.2field-weighted citation impact, top 50% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. The human factor H protein family - an update.Frontiers in immunology · 2024
    Review
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

Alyssa C GilmoreCentre for Inflammatory Disease, Imperial College London, UK.
Yuchun ZhangAlexion Pharmaceuticals, New Haven, Connecticut, USA.
H Terence CookCentre for Inflammatory Disease, Imperial College London, UK.
Deborah P LavinCentre for Inflammatory Disease, Imperial College London, UK.
Suresh KattiAlexion Pharmaceuticals, New Haven, Connecticut, USA.
Yi WangAlexion Pharmaceuticals, New Haven, Connecticut, USA.
Krista K JohnsonAlexion Pharmaceuticals, New Haven, Connecticut, USA.
SungKwon KimAlexion Pharmaceuticals, New Haven, Connecticut, USA.
Matthew C PickeringCentre for Inflammatory Disease, Imperial College London, UK. Electronic address: matthew.pickering@imperial.ac.uk.
Alexion Pharmaceuticals (United States) · USImperial College London · GB

Funding

Wellcome TrustWellcome Trust 212252/Z/18/Z
6 · The paper itself

Abstract

C3 glomerulopathy is characterized by accumulation of complement C3 within glomeruli. Causes include, but are not limited to, abnormalities in factor H, the major negative regulator of the complement alternative pathway. Factor H-deficient (Cfh

Indexed as

Complement C3ProperdinAnimalsComplement C3-C5 ConvertasesComplement C5Complement Factor HComplement Pathway, AlternativeImmunoglobulin GMiceComplement C3Complement C3-C5 ConvertasesComplement C5Complement Factor HImmunoglobulin GProperdincomplementglomerulonephritisimmunology

Identifiers

PMID33129896
PMCPMC7863913
OpenAlexW3097973272

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.